AIGH Capital Management LLC Sells 1,124,670 Shares of Delcath Systems, Inc. (NASDAQ:DCTH)

AIGH Capital Management LLC decreased its position in shares of Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) by 81.2% during the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 260,719 shares of the company's stock after selling 1,124,670 shares during the period. Delcath Systems accounts for approximately 1.4% of AIGH Capital Management LLC's portfolio, making the stock its 22nd largest holding. AIGH Capital Management LLC owned approximately 0.78% of Delcath Systems worth $3,319,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Soleus Capital Management L.P. purchased a new stake in Delcath Systems during the 4th quarter worth $9,644,000. Vivo Capital LLC increased its stake in Delcath Systems by 71.4% during the 4th quarter. Vivo Capital LLC now owns 1,708,579 shares of the company's stock worth $20,571,000 after buying an additional 711,574 shares during the period. Gilder Gagnon Howe & Co. LLC acquired a new position in Delcath Systems during the 4th quarter valued at about $7,371,000. Jane Street Group LLC boosted its stake in Delcath Systems by 1,364.6% during the 4th quarter. Jane Street Group LLC now owns 178,797 shares of the company's stock valued at $2,153,000 after purchasing an additional 166,589 shares during the period. Finally, Silverarc Capital Management LLC acquired a new position in Delcath Systems during the 4th quarter valued at about $1,870,000. Hedge funds and other institutional investors own 61.12% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on DCTH shares. Stephens reissued an "overweight" rating and set a $25.00 target price on shares of Delcath Systems in a research note on Monday, June 23rd. HC Wainwright reissued a "buy" rating and set a $29.00 target price (up from $24.00) on shares of Delcath Systems in a research note on Friday, May 23rd. Finally, Wall Street Zen lowered shares of Delcath Systems from a "buy" rating to a "hold" rating in a research note on Saturday, July 5th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $24.00.

Delcath Systems Stock Performance

Shares of DCTH stock traded up $0.53 during midday trading on Wednesday, reaching $11.61. 736,744 shares of the company were exchanged, compared to its average volume of 454,340. Delcath Systems, Inc. has a 12 month low of $7.17 and a 12 month high of $18.23. The company has a market cap of $404.33 million, a P/E ratio of -23.22 and a beta of 0.87. The company's 50 day moving average price is $14.59 and its two-hundred day moving average price is $13.83.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $0.03 EPS for the quarter, missing analysts' consensus estimates of $0.10 by ($0.07). Delcath Systems had a negative return on equity of 29.44% and a negative net margin of 26.38%. The business had revenue of $19.80 million during the quarter, compared to the consensus estimate of $16.83 million. As a group, sell-side analysts predict that Delcath Systems, Inc. will post -0.79 earnings per share for the current year.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.